Precision for Medicine CMO Harpreet Singh and Repertoire Immune Medicines CMO Robert Andtbacka discuss oncology clinical trial design, life on the biotech side, and advice for other CMOs

Two leaders from the Harvard Biotech Club talk about their experience in the club, its new podcast, The Pulse, and an upcoming career fair on September 19th

MassBio's CEO Kendalle Burlin O'Connell shares the details of today's just published 2025 Industry Snapshot - a key barometer of the health of biotech not just in Massachusetts, but as an industry

Two experts in genetic medicines, Devan Shah and Michelle Lynn Hall, discuss the recently announced federal funding cuts for mRNA research and what it means for this area of science going forward

Lisa Deschamps of AviadoBio and Richard Wilson of Astellas discuss the field of AAV gene therapy, and their partnership on AVB-101, an AAV gene therapy for frontotemporal dementia (FTD)

Biotech veteran Art Krieg explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP to create broad T-cell responses

Elias Zerhouni and Andy Plump discuss the future of multispecific biologics

Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech

Korro Bio's Ram Aiyar and Novo Nordisk's Uli Stilz discuss their RNA editing collaboration, the field of genetic medicine, and the future of drug discovery

Devan Shah and Namita Bisaria, experts in the field of RNA therapies, discuss the year ahead in RNA - opportunities, challenges, AI, fundraising, and more

The co-founder of the Scientific Citizenship Initiative discusses the importance of scientific communication, and trying to place STEM PhDs into the Mass. State House as full-time policy advisors

A patient advocacy group founded by two parents has partnered with a biotech company on a gene therapy for limb-girdle muscular dystrophy Type 2C/R5 - it was just cleared to start a clinical trial

Janssen's Elena Diez and Odyssey Therapeutics' Gary Glick share advice on success factors for pharma - biotech partnerships, and more

Kojin Therapeutics Chairman & CEO Harvey Berger shares an update on the company's progress and talks about the funding environment for earlier stage companies in biotech

Transcriptional regulation in disease: opportunities, challenges, and the future

A father and patient advocate discuss Canavan disease and a daughter's experience on a gene therapy clinical trial

Gene therapy experts TJ Cradick and Andrew Kernytsky discuss the issues surrounding unintended off-target editing of genetic tools like CRISPR

George Church on founder led companies, synthetic biology technologies, the future, and more

Gene therapy experts TJ Cradick and Kate Excoffon discuss using AAV gene therapy for cystic fibrosis

Immuno-Oncology experts Zhen Su and Kristen Hege discuss the latest in the field and preview #SITC24